In past 5 years, immune checkpoint inhibitors (ICIs), especially programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors, have significantly changed the treatment paradigm for patients with advanced NSCLC and provided long-term survival hope for patients with metastatic lung cancer. Here, CD274 is linked to non-small cell lung carcinoma.